One2Treat

Patients as Partners 2025 is next week! One2Treat is participating as an Associate Sponsor at this key event for patient-centricity in clinical research, happening March 17–19 in Boston. Visit us at Stand 16 in the exhibition hall !   Sébastien Coppe, PhD, One2Treat's CEO will give a talk on: “A patient-focused strategy to reduce trial sample size: Engaging patient representatives to reflect what matters most in treatment assessment.”   Please consider also connecting with Jean-Christophe Chiêm, PhD, and Samuel Salvaggio, PhD, who will also be attending. They will be happy to discuss how to build multi-dimensional primary endpoints that can better reflect patient experiences.   Event details and registration here : https://lnkd.in/ervZ2z3k   Use our code ONE2T20 for a 20% discount on registration. #clinicalresearch #PatientsasPartners2025 #patientcentricity

Curious how One2Treat puts patient interests at the heart of clinical trials? Take just 3 minutes to learn how we integrate all patient-relevant outcomes to fully assess the 𝐧𝐞𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐛𝐞𝐧𝐞𝐟𝐢𝐭.    The Net Treatment Benefit (NTB) is a comprehensive estimator of treatment effect for randomized clinical trials 👇

We are proud to be an Associate Sponsor at #PatientsasPartners2025 from March 17-19 in Boston - a key event driving patient-centricity in clinical research.   Join our CEO, Sébastien Coppe, PhD, as he takes the stage to present: “𝐀 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐭𝐨 𝐫𝐞𝐝𝐮𝐜𝐞 𝐭𝐫𝐢𝐚𝐥 𝐬𝐚𝐦𝐩𝐥𝐞 𝐬𝐢𝐳𝐞: Engaging patient representatives to reflect what matters most in treatment assessment”   One2Treat colleagues Jean-Christophe Chiêm, PhD & Samuel Salvaggio, PhD will also be attending – ready to discuss how we’re revolutionizing treatment assessments by engaging patients early to create multi-dimensional primary endpoints that reflect patient experiences.   We’ll have a presence in the exhibition hall at Stand 16 — come by to learn more!   Looking to attend? All the event info is here 👉 https://lnkd.in/ervZ2z3k Use our unique discount code ONE2T20 for 20% off registration!   Let’s put patients at the heart of clinical research! ❤️   #clinicalresearch #patientfocuseddrugdevelopment

One2Treat's founder Marc Buyse just contributed to The Lancet Group : Oncology, with an article on “𝘋𝘰𝘴𝘦 𝘰𝘱𝘵𝘪𝘮𝘪𝘴𝘢𝘵𝘪𝘰𝘯 𝘵𝘰 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘢𝘤𝘤𝘦𝘴𝘴 𝘵𝘰 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘤𝘢𝘯𝘤𝘦𝘳 𝘮𝘦𝘥𝘪𝘤𝘪𝘯𝘦𝘴.” Cancer drugs are often approved at doses and schedules that maximize statistical significance in trials, but not necessarily affordability, tolerability, or accessibility. This paper highlights how optimizing doses and schedules can retain therapeutic benefits while reducing toxicity and cost, improving global access to life-saving treatments. Key points discussed include:    •       Many cancer drugs could be equally effective at lower doses or with less frequent administration  •       Dose optimization can significantly reduce treatment costs, making life-saving medicines more accessible  •       A call for adopting innovative methodologies like Generalized Pairwise Comparisons to assess treatment effects more comprehensively. At One2Treat, we’re actively addressing these challenges by developing and implementing advanced solutions that prioritize patient-centered outcomes through innovative clinical trial design. 📖 Read the full article here: https://lnkd.in/esFdpRXz #Oncology #ClinicalTrials #Innovation

For Rare Disease Day, One2Treat CEO Sébastien Coppe, PhD and CMO Pascal Piedbois were invited by IDDI - Regulatory Statistics & Clinical Data Science Experts to present a webinar on: “𝘉𝘦𝘺𝘰𝘯𝘥 𝘛𝘳𝘢𝘥𝘪𝘵𝘪𝘰𝘯𝘢𝘭 𝘌𝘯𝘥𝘱𝘰𝘪𝘯𝘵𝘴: 𝘈 𝘗𝘢𝘵𝘪𝘦𝘯𝘵-𝘍𝘰𝘤𝘶𝘴𝘦𝘥 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩 𝘵𝘰 𝘌𝘯𝘩𝘢𝘯𝘤𝘪𝘯𝘨 𝘙𝘢𝘳𝘦 𝘋𝘪𝘴𝘦𝘢𝘴𝘦 𝘛𝘳𝘪𝘢𝘭𝘴.” At One2Treat, we believe traditional endpoints don’t always capture what matters most to patients. By incorporating multiple clinical outcomes into a single Net Treatment Benefit (NTB) assessment, we can: • Leverage more of the trial data collected • Improve patient-centricity and clinical relevance • Optimize trial design, reducing sample size and timelines They illustrate this approach with a real-world Sjögren’s syndrome trial case study. 📺 Watch the webinar on YouTube: https://lnkd.in/ekrj92ZB #RareDiseaseDay #PatientCentricity #ClinicalResearch

Up to 𝟯𝟯% 𝗼𝗳 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗮𝗶𝗹 due to recruitment challenges, making it difficult to reach the required sample size to demonstrate treatment efficacy. In his latest contribution to ACRP - Association of Clinical Research Professionals, Tom Mann discusses innovative solutions to address this challenge.   There is a need for 𝗿𝗶𝗴𝗼𝗿𝗼𝘂𝘀 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗰𝗲𝗻𝘁𝗲𝗿𝗲𝗱 approaches that leverage all relevant clinical data, rather than relying on a single primary outcome, to assess treatment effects more efficiently. 𝗧𝗵𝗲 𝗡𝗲𝘁 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗕𝗲𝗻𝗲𝗳𝗶𝘁 (𝗡𝗧𝗕) provides a more powerful way to evaluate treatments by integrating multiple clinical outcomes into a single analysis. This means: • 𝗦𝗺𝗮𝗹𝗹𝗲𝗿, 𝗳𝗮𝘀𝘁𝗲𝗿 𝘁𝗿𝗶𝗮𝗹𝘀 – reducing sample size while maintaining statistical rigor • 𝗠𝗼𝗿𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁-𝗳𝗼𝗰𝘂𝘀𝗲𝗱 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 – prioritizing all relevant outcomes based on clinical importance • 𝗕𝗲𝘁𝘁𝗲𝗿 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗶𝗻𝗴 – providing a more comprehensive assessment of a treatment’s overall benefit-risk profile In rare diseases, where 𝗲𝘃𝗲𝗿𝘆 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀, innovative methods like NTB can accelerate research and 𝗯𝗿𝗶𝗻𝗴 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗳𝗮𝘀𝘁𝗲𝗿. 📖 Read more https://lnkd.in/e6qf-39P #ClinicalTrials #RareDiseases #Innovation #PatientCentricity

Earlier this month, our CEO Sébastien Coppe, PhD, took the stage at the 𝐒𝐂𝐎𝐏𝐄 𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 & 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐢𝐧𝐠 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞, where he joined other startup leaders to discuss how emerging companies are shaping the future of clinical trials. Later, he sat down for an interview with Donald Tracy, MA from Applied Clinical Trials Magazine to dive deeper into these topics.   During the interview, he was asked two key questions:   🔹 𝐖𝐡𝐚𝐭 𝐰𝐚𝐬 𝐭𝐡𝐞 𝐩𝐚𝐧𝐞𝐥 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐚𝐛𝐨𝐮𝐭? Sebastien shared how startups—including One2Treat—are delivering practical solutions to make clinical research genuinely more patient-centric, moving beyond the buzzwords. He highlighted how these innovations help pharma sponsors and CROs meaningfully integrate new approaches into clinical development. These themes were central to the Venture Innovation & Partnering Conference, where Sebastien emphasized the growing need for real-world adoption rather than just rhetoric.   🔹 𝐖𝐡𝐚𝐭’𝐬 𝐭𝐡𝐞 𝐛𝐢𝐠𝐠𝐞𝐬𝐭 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐟𝐨𝐫 𝐎𝐧𝐞𝟐𝐓𝐫𝐞𝐚𝐭? While regulatory bodies provide guidance on patient-focused drug development, pharma sponsors often hesitate to embrace innovation, unsure how to translate these innovative ideas into practice, partly due to uncertainty about future regulatory discussions. One2Treat’s objective is to reassure sponsors and manage risks, helping them move from cautious exploration to real adoption.   We’re excited to be part of this evolving conversation and grateful to Donald Tracy, MA and Applied Clinical Trials for the opportunity to share our perspective!   Watch part 1 of the interview here 👉https://lnkd.in/dzjUec_d   #SCOPE2025 #ClinicalTrials #PatientCentric

🔥 The final episode of the #IDDI Podcast series on the FDA’s Project Optimus is here!   We had the pleasure of joining IDDI - Regulatory Statistics & Clinical Data Science Experts to discuss the role of the Net Treatment Benefit (NTB) in dose finding and dose optimization for #oncology trials.    One2Treat Chief Medical Officer Pascal Piedbois said: "𝘈𝘴 𝘢𝘯 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘪𝘴𝘵, 𝘐 𝘴𝘦𝘦 𝘗𝘳𝘰𝘫𝘦𝘤𝘵 𝘖𝘱𝘵𝘪𝘮𝘶𝘴 𝘢𝘴 𝘢𝘯 𝘦𝘹𝘤𝘪𝘵𝘪𝘯𝘨 𝘤𝘢𝘵𝘢𝘭𝘺𝘴𝘵 𝘧𝘰𝘳 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘥𝘰𝘴𝘦 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘢𝘵𝘪𝘰𝘯. 𝘐𝘯 𝘮𝘺 𝘳𝘰𝘭𝘦, 𝘵𝘩𝘪𝘴 𝘍𝘋𝘈 𝘪𝘯𝘪𝘵𝘪𝘢𝘵𝘪𝘷𝘦 𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘢 𝘷𝘢𝘭𝘶𝘢𝘣𝘭𝘦 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺 𝘵𝘰 𝘵𝘩𝘪𝘯𝘬 𝘤𝘳𝘦𝘢𝘵𝘪𝘷𝘦𝘭𝘺. 𝘐 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘖𝘯𝘦2𝘛𝘳𝘦𝘢𝘵 𝘪𝘴 𝘸𝘦𝘭𝘭 𝘱𝘰𝘴𝘪𝘵𝘪𝘰𝘯𝘦𝘥 𝘵𝘰 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘦, 𝘰𝘧𝘧𝘦𝘳𝘪𝘯𝘨 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘴 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘢 𝘕𝘦𝘵 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘉𝘦𝘯𝘦𝘧𝘪𝘵 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩 𝘶𝘴𝘪𝘯𝘨 𝘮𝘶𝘭𝘵𝘪𝘱𝘭𝘦 𝘰𝘶𝘵𝘤𝘰𝘮𝘦 𝘮𝘦𝘵𝘩𝘰𝘥𝘰𝘭𝘰𝘨𝘺."   Senior Trial Design Lead Rudradev Sengupta added: "𝘉𝘺 𝘪𝘯𝘵𝘦𝘨𝘳𝘢𝘵𝘪𝘯𝘨 𝘎𝘗𝘊/𝘕𝘛𝘉 𝘪𝘯𝘵𝘰 𝘦𝘢𝘳𝘭𝘺 𝘥𝘰𝘴𝘦 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘢𝘵𝘪𝘰𝘯, 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭𝘴 𝘤𝘢𝘯 𝘣𝘦 𝘮𝘰𝘳𝘦 𝘢𝘥𝘢𝘱𝘵𝘪𝘷𝘦, 𝘦𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘵, 𝘢𝘯𝘥 𝘱𝘢𝘵𝘪𝘦𝘯𝘵-𝘧𝘰𝘤𝘶𝘴𝘦𝘥. 𝘛𝘩𝘦 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘨𝘢𝘪𝘯𝘦𝘥 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘪𝘯𝘪𝘵𝘪𝘢𝘭 𝘱𝘩𝘢𝘴𝘦𝘴 𝘤𝘢𝘯 𝘩𝘦𝘭𝘱 𝘶𝘴 𝘳𝘦𝘧𝘪𝘯𝘦 𝘥𝘰𝘴𝘦𝘴, 𝘥𝘦𝘴𝘪𝘨𝘯 𝘴𝘮𝘢𝘳𝘵𝘦𝘳 𝘵𝘳𝘪𝘢𝘭𝘴, 𝘢𝘯𝘥 𝘦𝘯𝘴𝘶𝘳𝘦 𝘵𝘩𝘢𝘵 𝘵𝘩𝘦 𝘮𝘰𝘴𝘵 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘴𝘢𝘧𝘦𝘴𝘵 𝘥𝘰𝘴𝘦 𝘪𝘴 𝘵𝘦𝘴𝘵𝘦𝘥 𝘪𝘯 𝘭𝘢𝘵𝘦𝘳 𝘱𝘩𝘢𝘴𝘦𝘴, 𝘶𝘭𝘵𝘪𝘮𝘢𝘵𝘦𝘭𝘺 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘨𝘰𝘢𝘭𝘴 𝘰𝘧 𝘗𝘳𝘰𝘫𝘦𝘤𝘵 𝘖𝘱𝘵𝘪𝘮𝘶𝘴."   🎧 Tune in now 👉 https://lnkd.in/ek_ZNRc3

One2Treat Senior Trial Design Lead Samuel Salvaggio, PhD was interviewed by Applied Clinical Trials Magazine during #SCOPEsummit, where he shared his focus on how 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐯𝐨𝐢𝐜𝐞𝐬 𝐜𝐚𝐧 𝐛𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐥𝐲 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐢𝐧𝐭𝐨 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥 𝐝𝐞𝐬𝐢𝐠𝐧. While the FDA has issued guidance on patient-centricity, it lacks detailed implementation strategies. Conferences like SCOPE provide a platform to discuss concrete methods for incorporating patient perspectives into trial protocol development.   Samuel also highlighted the importance of 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐬𝐢𝐭𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐨𝐫𝐬 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐯𝐞𝐬—key stakeholders in ensuring trials reflect real patient needs, ultimately boosting trial success and engagement.   #clinicaltrialdesign #ClinicalTrials #patientfocus 

We're pleased to share that the first edition of "𝘏𝘢𝘯𝘥𝘣𝘰𝘰𝘬 𝘰𝘧 𝘎𝘦𝘯𝘦𝘳𝘢𝘭𝘪𝘻𝘦𝘥 𝘗𝘢𝘪𝘳𝘸𝘪𝘴𝘦 𝘊𝘰𝘮𝘱𝘢𝘳𝘪𝘴𝘰𝘯𝘴: 𝘔𝘦𝘵𝘩𝘰𝘥𝘴 𝘧𝘰𝘳 𝘗𝘢𝘵𝘪𝘦𝘯𝘵-𝘊𝘦𝘯𝘵𝘳𝘪𝘤 𝘈𝘯𝘢𝘭𝘺𝘴𝘪𝘴" has been published by Taylor & Francis Group. This work reflects months of careful effort by a dedicated team of six editors: Marc Buyse, Vaiva Deltuvaite - Thomas, Mickaël De Backer, Johan Verbeeck, Everardo Saad, Geert Molenberghs and 31 contributing authors (tagged below) including two One2Treat colleagues Jean-Christophe Chiêm, PhD & Samuel Salvaggio, PhD.   We couldn't have captured the book’s essence better than this quote from the postface:   “𝘛𝘩𝘪𝘴 𝘣𝘰𝘰𝘬 𝘴𝘵𝘢𝘯𝘥𝘴 𝘢𝘴 𝘢 𝘨𝘶𝘪𝘥𝘪𝘯𝘨 𝘣𝘦𝘢𝘤𝘰𝘯 𝘧𝘰𝘳 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘦𝘳𝘴, 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩𝘦𝘳𝘴, 𝘢𝘯𝘥 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘴, 𝘴𝘱𝘢𝘳𝘬𝘪𝘯𝘨 𝘵𝘩𝘦 𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘰𝘧 𝘧𝘪𝘵-𝘧𝘰𝘳-𝘥𝘰𝘴𝘴𝘪𝘦𝘳 𝘵𝘳𝘪𝘢𝘭𝘴 𝘪𝘯𝘵𝘰 𝘢𝘨𝘪𝘭𝘦 𝘴𝘵𝘶𝘥𝘪𝘦𝘴 𝘵𝘢𝘪𝘭𝘰𝘳𝘦𝘥 𝘧𝘰𝘳 𝘪𝘯𝘧𝘰𝘳𝘮𝘦𝘥 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴.” Francesco Pignatti, Head of the Office of Oncology and Haematology, European Medicines Agency, Amsterdam, the Netherlands.   The book sets the stage for a new era of clinical research where patient-centered approaches lead the way.   For more info 👉 https://lnkd.in/gKafqffv Vittoria Ardito, Stef Baas, Richard Boucherie, Edgar Brunner, Tomasz Burzykowski, Oriana Ciani, Laura del Carpio, Alexandra Dima, Scott Evans, Michael Fay, Joris Giai, Toshimitsu Hamasaki, Peter Kapitein, Michal Kicinski, Frank Konietschke, Catherine Legrand, Natalia Oprea, Brice Ozenne, Gene Pennello, Julien Peron, Thibaut Reverdy, Frank W. Rockhold, PhD, Matthieu Roustit, Stephen Schüürhuis, Olivier THAS, Jan Verwerft, Pascal Vranckx, Rebecca (Becky) Wilgus.   #Research #Collaboration #Publication #PatientCentricity